• 제목/요약/키워드: Macrocephaly

검색결과 28건 처리시간 0.056초

Cowden 증후군 1례의 장기 추적 관찰 (Long-term Follow-up of a Case of Cowden Syndrome)

  • 최선윤;김흥식;박경식;이희정;오훈규;황진복
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제7권1호
    • /
    • pp.112-118
    • /
    • 2004
  • 위장관에서 용종성 병변이 있을 때 Cowden 증후군의 감별이 필요하며 소아 연령에서는 모든 증상이 발현되지 않으므로 추적 관찰이 필요하리라 판단된다. 특히, 식도의 극세포증은 모습이 독특하고 거의 대부분의 증례에서 보고되고 있어 최근 Cowden 증후군의 진단 시 질병특유의 기준으로 활용되기도 하므로 특히 염두에 둘 필요가 있으며, 그러나 소아 연령에서는 적절한 나이가 될 때까지는 극세포증의 발현이 지연될 수 있음도 반드시 고려하여야 할 것으로 판단된다.

  • PDF

Robinow 증후군 환아의 전신마취를 이용한 치료증례보고 (TREATMENT OF THE CHILD WITH ROBINOW SYNDROME UNDER GENERAL ANESTHESIA : A CASE REPORT)

  • 박재홍;이긍호
    • 대한소아치과학회지
    • /
    • 제23권3호
    • /
    • pp.601-608
    • /
    • 1996
  • 저자는 전반적인 치아우식증을 주소로 개인 의원에서 경희대학교병원 소아치과에 의뢰된 10세 여아에서 Robinow syndrome 의 드문 증례의 치료를 시행하고 문헌을 고찰하여 다 음과 같은 결론을 얻었다. 1. 전신소견으로 전두부 돌출, 양안격리, 넓은 안검렬, 들창코 등을 보이는 태아모습의 특정적 안모와 작은키, 짧은 팔, 굽은 손가락, 생식기의 미발육 등이 관찰되었고 전반적인 발육지연이 있었다. 2. 구내소견으로 치아우식, 치아총생, 구개수의 미발육, 수술받은 구개열, 구호흡이 관찰되었다. 3. 이 증후군에서 드물게 보여지는 정신지체, 청각장애, 삼출성 중이염을 동반하였다. 4. 가족력은 발견할수 없었다. 5. 전신마취하에 전반척인 치과치료와 이비인후과치료를 함께 시행하였다. 6. Robinow 증후군은 여러 합병증을 수반할 수 있으므로 타과와의 협력하에 전반적인 검사를 시행하고 포괄적인 협력진료가 요구된다.

  • PDF

Treatment of Keratocystic Odontogenic Tumors in Nevoid Basal Cell Carcinoma Syndrome

  • Ryu, Hyun-Ho;Shin, Dong-Yoon;Ryu, Seok-Hwan;Kim, Taek-Woo;Lee, Jong-Bum;Kim, Bok-Joo;Kim, Chul-Hoon
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • 제36권1호
    • /
    • pp.7-12
    • /
    • 2014
  • Nevoid basal cell carcinoma syndrome (NBCCS) is inherited as an autosomal dominant trait with variable conditions, including multiple basal cell carcinoma, numerous keratocystic odontogenic tumors (KOTs) in the jaws, ectopic calcification of the falx cerebri, bifid ribs, macrocephaly, kyphoscoliosis, cleft palate, frontal and temporal bossing, mild ocular hypertelorism, mild mandibular prognathism, vertebral fusion, and so on. A 16-year-old boy visited the Dong-A University Medical Center, requiring diagnosis and treatment of multiple cystic lesions. He presented with many conditions related to NBCCS, including multiple KOTs, bifid rib, cleft lip, frontal bossing, mild ocular hypertelorism, and mild mandibular prognathism. No characteristic cutaneous manifestations (nevoid basal cell carcinoma) were observed in this patient. We report on a case of multiple KOTs associated with NBCCS with a review of the literature.

Costello 증후군 3례 (Costello syndrome: three sporadic cases)

  • 김지윤;김미정;송은송;조영국;최영륜;마재숙
    • Clinical and Experimental Pediatrics
    • /
    • 제50권10호
    • /
    • pp.1024-1029
    • /
    • 2007
  • Costello 증후군은 특징적 얼굴 형태(coarse face), 발달 장애, 지능 저하, 성장 지연, 신경학적 이상, 심근증, 피부 병변, 수유 장애, 상대적 대두증, 소관절의 과신전, 고형종 발생 증가 등을 특징으로 하는 드문 증후군으로 1977년 Costello에 의해 처음으로 보고되었으며, 이후 전세계적으로 약 100례 이상이 보고되었다. 최근 Costello 증후군은 HRAS 유전자 내의 glycine 12 또는 13 codon을 침범하는 de novo mutation에 의해 발생하는 것으로 알려져 있다. 저자들은 특징적인 얼굴 형태와 지능 저하, 대두증, 손과 발의 과도한 주름, 비후성 심근증과 심방성 빈맥으로 특징지어지는 Costello 증후군으로 진단된 환아 3례를 경험하였기에 이를 보고하는 바이다.

기저세포모반증후군과 연관된 다발성 치성각화방종의 치료시 술전 조대술과 술후 교정적 맹출의 사용 치험 1례 (CASE REPORT OF TREATMENT OF MULTIPLE ODONTOGENIC KERATOCYSTS WITH BASAL CELL NEVUS SYNDROME USING PREOPERATIVE MARSUPIALIZATION AND ORTHODONTIC EXTRUSION)

  • 강태인;박영주;남정훈;안장훈;강혜진;송준호;정재안;신진업
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • 제31권5호
    • /
    • pp.429-434
    • /
    • 2009
  • Basal cell nevus syndrome is a rare inherited disorder characterized by mulitple cutaneous basal cell carcinoma, pits of the palms and soles, cysts of the jaws, skeletal abnormalities and ectopic calcifications. Currently there are new lines of investigation based on biomolecular studies, which aim at identifying the molecules responsible for these cysts and thus early allowing an early diagnosis of these patients. We report a case of a 9-year-old boy with the various manifestation of basal cell nevus syndrome, which are multiple odontogenic keratocysts, pits of the soles, bifid ribs, ectopic calcification, macrocephaly, and hypertelorism, etc. Total five odontogenic keratocysts were found. For the reduction of the size of the odon-togenic keratocysts, following preoperative marsupialization, there were surgically enucleated. And the impacted upper right lateral incisor and canine are tracted orthodontically.

Two Korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in SNX14

  • Kim, Ae Ryoung;Lee, Jong-Mok;Seo, Go Hun;Lee, Sang In;Bae, Hyunwoo;Lee, Yun Jeong
    • Journal of Genetic Medicine
    • /
    • 제18권2호
    • /
    • pp.127-131
    • /
    • 2021
  • Autosomal recessive spinocerebellar ataxia 20 (SCAR20; OMIM #616354) is a recently described disorder that is characterized by ataxia, intellectual disability, cerebellar atrophy, macrocephaly, coarse face, and absent speech. It is caused by loss-of-function mutations in SNX14. To date, all cases with homozygous pathogenic variants have been identified in consanguineous families. This report describes the first Korean cases of SCAR20 family caused by homozygous variants in SNX14. Two siblings were referred to our clinic because of severe global developmental delay. They presented similar facial features, including a high forehead, long philtrum, thick lips, telecanthus, depressed nasal bridge, and broad base of the nose. Because the older sibling was unable to walk and newly developed ataxia, repeated brain magnetic resonance imaging (MRI) was performed at the age of 4 years, revealing progressive cerebellar atrophy compared with MRI performed at the age of 2 years. The younger sibling's MRI revealed a normal cerebellum at the age of 2 years. Whole-exome sequencing was performed, and homozygous variants, such as c.2746-2A>G, were identified in SNX14 from the older sibling. Sanger sequencing confirmed homozygous SNX14 variants in the two siblings as well as a heterozygous variant in both parents. This report extends our knowledge of the phenotypic and mutational spectrum of SCAR20. We also highlight the importance of deep phenotyping for the diagnosis of SCAR20 in individuals with developmental delay, ataxia, cerebellar atrophy, and distinct facial features.

생화학적 검사 및 분자유전학적 검사에 의해 뮤코다당증 제3A형으로 진단된 한국인 환자의 증례 보고 (A Case Report for a Korean Patient with Mucopolysaccharidosis IIIA Confirmed by Biochemical and Molecular Genetic Investigation)

  • 김보람;조성윤;손영배;박형두;이수연;송정한;진동규
    • 대한유전성대사질환학회지
    • /
    • 제15권1호
    • /
    • pp.44-48
    • /
    • 2015
  • 뮤코다당증 제3A형(Mucopolysaccharidosis IIIA, Sanfillippo syndrome type A)은 heparan sulfate 대사에 관여하는 heparan N-sulfatase의 결핍으로 유발되는 리소좀 축적 질환이다. 본 연구는 대두증과 발달 지연을 보이는 5세 환아를 대상으로 하였다. 환아 소변의 glycosaminoglycan은 26 g/moL creatinine으로 증가되어 있었고(참고치: <7 g/moL creatinine), 소변의 전기영동 검사에서는 heparan sulfate 분획이 뚜렷하게 관찰되었다. 피부 섬유아세포에서 측정한 heparan N-sulfatase 활성도는 0.2 pmol/min/mg protein으로 매우 감소되어 있었다(참고치: 9-64 pmol/min/mg protein). 중합효소연쇄반응-염기서열분석법에 의한 SGSH 유전자 검사에서는 c.1040C>T (p.S347F) 및 c.703G>A (p.D235N) 돌연변이가 각각 이형접합체 양상으로 나타났다. 이에 생화학적 검사 및 분자유전학적 검사를 통해 뮤코다당증 제3A형으로 확진된 첫 번째 한국인 사례를 보고하는 바이다.

5세 미만 뮤코다당체침착증 환자에서의 효소 대체 요법 (Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis and Are younger than 5 years old)

  • 박성원;손영배;김세화;조성윤;지선태;진동규
    • 대한유전성대사질환학회지
    • /
    • 제10권1호
    • /
    • pp.59-66
    • /
    • 2010
  • Enzyme replacement of therapy (ERT) is one of the most promising therapeutic strategies for the treatment of lysosomal storage disorders. ERT is available in three types of Mucopolysaccharidosis (MPS): for MPS I (Aludrazyme$^{(R)}$), MPS II (Elaprase$^{(R)}$) and MPS VI (Naglazyme$^{(R)}$) patients who are over 5 years old. But recently, early diagnosis can be done by expert clinicians and even in prenatal case. We describe the case of ERT under 5 years old MPS patients. Up to June, 2010 in Samsung Medical Center, there are 6patients who were diagnosed as MPS and started ERT under 5 years old. 3 patients were MPS I, 3 patients were MPS II. 2 patient who was diagnosed as MPS I was female and others were male. Their age at diagnosis were 4 to 37month-old (4, 13, 16, 25, 27, 37 month-old) and they are now 9 to 60 month-old (9, 39, 32, 81, 60 month-old). The youngest patient was started ERT at 4 month-old and others were started at their 13 to 49 month-old (13, 29, 27, 28, 49 month-old). First manifested symptoms of patients were macrocephaly, kyphosis and coarse face appearance. Especially, in 2 of them, one was MPS I and the other was MPS II had elder brother with same disease. And the youngest one was diagnosed by the iduronate-2-sulfatase (IDS) gene analysis from chorionic villi sampling. His mother knew that she was a heterozygous carrier of IDS gene mutation because her younger brother died from MPS II. All of them confirmed as MPS by the enzyme assay in leukocytes and fibroblast skin culture. We started ERT with ${\alpha}$-L-iduronidase(Aldurazyme$^{(R)}$) to MPS I and did recombinant human iduronate-2-sulfatase (Elaprase$^{(R)}$) to MPS II patients as recommended dose as over 5 years old. But for MPS II patient who was 4 month old, we started ERT by recombinant human IDS (Elaprase$^{(R)}$) with reduced dose 0.1 mg/kg and increased dose every 2 weeks by 0.1mg/kg up to 0.5mg/kg IV infusion. During ERT, all patients had no adverse effects and the excretion of GAGs were decreased. We have evaluated other clinical symptoms such as liver/ spleen volume, heart function and neurologic evaluation. We describe a successful ERT to MPS I and MPS II patient under 5 years old without any adverse event. It indicates that ERT in young children are well tolerated and that it has several effects which may confer clinical benefits with long-term therapy.

  • PDF